ECONOMIC EVALUATION OF LUNG CANCER THERAPIES ASSESSED BY THE FRENCH HTA AGENCY (HAS): A REVIEW OF 20 HTA SUBMISSIONS (2015-2026)
Author(s)
Samar GARMAN, PharmD, Cléa SAMBUC, PhD, Lucile Marié, MSc, Bertrand Tehard, MSc, PhD.
Vyoo Agency, Paris, France.
Vyoo Agency, Paris, France.
OBJECTIVES: Lung cancer remains the leading cause of cancer-related mortality in France, with 52,777 new cases diagnosed in 2023. Major therapeutic advances have substantially improved outcomes, with real-world evidence showing a 26.6% increase in 2-year overall survival between 2000 and 2026. Most innovative therapies have undergone economic evaluation within the French health technology assessment (HTA) process. This study examined modelling approaches, cost-effectiveness outcomes, and CEESP appraisal decisions for lung cancer treatments.
METHODS: A retrospective review of CEESP opinions was conducted using the Vyoo Agency HTA database. Economic evaluations published between January 2015 and March 2026 for lung cancer treatments across disease stages were included.
RESULTS: Twenty reimbursement submissions underwent CEESP assessment. Treatments progressively shifted from second line to first-line settings and subsequently to earlier-stage disease. Most evaluations used three state partitioned survival models. Time horizons ranged from 5 to 20 years, with shorter horizons in advanced disease and longer horizons in early stage settings.Among 23 analyses including subpopulations, 52% used a single comparator; chemotherapy was the most frequent comparator (50%), followed by best supportive care (25%).CEESP validated results per QALY in 75% of submissions (15/20) and rejected them in 25% (5/20). Among validated submissions, 33% received ASMR III (moderate added benefit), 60% ASMR IV (minor added benefit), and 7% ASMR V (no added benefit) ratings. For ASMR III therapies, validated ICERs ranged from €75,000 to €175,000 per QALY gained, whereas greater variability was observed for ASMR IV therapies Greater variability was observed among ASMR IV therapies, with two interventions assessed as dominant or dominated and ICERs ranging from €88,193 to €297,191 per QALY gained.
CONCLUSIONS: Despite evolving treatment pathways and earlier intervention settings, methodological approaches remain relatively consistent. Understanding these trends and CEESP appraisal patterns may help inform future economic evaluations and HTA submissions in France.
METHODS: A retrospective review of CEESP opinions was conducted using the Vyoo Agency HTA database. Economic evaluations published between January 2015 and March 2026 for lung cancer treatments across disease stages were included.
RESULTS: Twenty reimbursement submissions underwent CEESP assessment. Treatments progressively shifted from second line to first-line settings and subsequently to earlier-stage disease. Most evaluations used three state partitioned survival models. Time horizons ranged from 5 to 20 years, with shorter horizons in advanced disease and longer horizons in early stage settings.Among 23 analyses including subpopulations, 52% used a single comparator; chemotherapy was the most frequent comparator (50%), followed by best supportive care (25%).CEESP validated results per QALY in 75% of submissions (15/20) and rejected them in 25% (5/20). Among validated submissions, 33% received ASMR III (moderate added benefit), 60% ASMR IV (minor added benefit), and 7% ASMR V (no added benefit) ratings. For ASMR III therapies, validated ICERs ranged from €75,000 to €175,000 per QALY gained, whereas greater variability was observed for ASMR IV therapies Greater variability was observed among ASMR IV therapies, with two interventions assessed as dominant or dominated and ICERs ranging from €88,193 to €297,191 per QALY gained.
CONCLUSIONS: Despite evolving treatment pathways and earlier intervention settings, methodological approaches remain relatively consistent. Understanding these trends and CEESP appraisal patterns may help inform future economic evaluations and HTA submissions in France.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
HTA94
Topic
Economic Evaluation, Health Policy & Regulatory, Health Technology Assessment
Topic Subcategory
Decision & Deliberative Processes, Value Frameworks & Dossier Format
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology